奧麥羅製藥 OMER 深 滬
已收盤 04-02 16:00:00 美东时间
10.90
-1.180
-9.77%
華盛通- 最 高11.8109
- 今 開11.62
- 成交量 183.73万股
- 最 低 10.8241
- 昨 收 12.08
- 總市值 7.73亿
- 52周最高 17.65
- 市盈率 靜 --
- 換手率 2.59%
- 52周最低 2.95
- 委 比 -81.82%
- 總股本 7090.05万
- 歷史最高 30.23
- 量 比 1.03
- 振 幅 8.17%
- 歷史最低 0.92
- 每 手 1
- 風險率 3.60%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Omeros Turns Corner With Novo Deal, YARTEMLEA Launch
Omeros Corporation (($OMER)) has held its Q4 earnings call. Read on for the mai...
04-04 08:28
美股牛股 | 脑再生科技飙升32%，拟增发最高5亿美元股票；DEFT大涨24%
脑再生科技飙升32%，拟增发最高5亿美元股票；DEFT大涨24%，财报强劲25年扭亏为盈；PLAY大涨16%，Q4同比转亏，但CEO称26财年将创造1亿美元现金流>>
04-02 18:58
Omeros rises as Novo deal boosts Q4 earnings
Omeros Corporation (OMER) added ~14%, posting its best intraday gain since December on Wednesday after the company reported better-than-expected earnings with its Q4 2025 financials, thanks mainly to ...
04-02 02:09
Omeros Q4 Adj. EPS $3.14 Beats $(0.57) Estimate
Omeros (NASDAQ:OMER) reported quarterly earnings of $3.14 per share which beat the analyst consensus estimate of $(0.57) by 650.88 percent. This is a 598.41 percent increase over losses of $(0.63) per share from the same
04-01 04:06
Earnings Scheduled For March 31, 2026
Companies Reporting Before The Bell • Bitfarms (NASDAQ:BITF) is projected to re...
03-31 19:11
Omeros Q4 2025 Earnings Preview
Omeros (OMER) is scheduled to announce Q4 earnings results on Monday, March 30th, after market close. The consensus EPS Estimate is $0.36 (+166.7% Y/Y) and the consensus Revenue Estimate is $0M Over t...
03-31 05:35
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results
Omeros updates its financial calendar; management hosts a conference call and webcast for FY2025 results Omeros will release financial results for the fourth quarter and year ended Dec. 31, 2025 on March 31, 2026 after market close. A conference call and webcast is scheduled for March 31, 2026 at 4:
03-26 20:45
Omeros to host EBMT industry session on TA-TMA treatment advances
Omeros to host EBMT industry session on TA-TMA treatment advances Omeros will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm to 4pm CET in Madrid. The session is titled “Advances in TA-TMA Treatme
03-21 15:23
Omeros Completes Initial Trial In Nonhuman Primates To Evaluate OncotoX-AML Cancer Therapeutic Platform
Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML
02-17 21:46
